AASDL 2012: A shift to direction action in hepatitis C?
This article was originally published in Scrip
New antivirals that that allow for interferon-sparing regimens for treating hepatitis C drugs are set to dominate pharmaceutical thinking at this year’s meeting of the American Association for the Study of Liver Diseases in Boston on 9-13 November.
You may also be interested in...
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.